The prognostic significance of clinical and pathological features in hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 8, Issue 2, 2002, Pages 193-199

  Qin, Lun Xiu ^a   Tang, Zhao You ^a  

^a ZHONGSHAN HOSPITAL OF FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; BETA INTERFERON; BILIRUBIN; ESTROGEN RECEPTOR; FIBRINOGEN; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; IODINATED POPPYSEED OIL; IODINE 131; MESSENGER RNA; PICIBANIL; SEX HORMONE;

AGE; ALBUMIN BLOOD LEVEL; ARTIFICIAL EMBOLISM; BLEEDING; BLOOD TRANSFUSION; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CELL DIFFERENTIATION; CELL INFILTRATION; CLINICAL FEATURE; COMPARATIVE STUDY; DISEASE ASSOCIATION; DISEASE MARKER; DOSE RESPONSE; DRUG EFFICACY; ENCAPSULATION; HEPATITIS; HISTOPATHOLOGY; HUMAN; INJECTION; INVASIVE CARCINOMA; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION; LIVER HILUS; LIVER RESECTION; LIVER TRANSPLANTATION; LIVER TUMOR; LYMPH NODE METASTASIS; METASTASIS POTENTIAL; MORPHOLOGY; OCCLUSION; OUTCOMES RESEARCH; PATHOLOGY; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; SEX DIFFERENCE; TUMOR VOLUME;

EID: 0036232361     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v8.i2.193     Document Type: Review

References (95)

1. Estimates of the worldwide mortality from 25 cancers in 25 cancers in 1990
2. Cancer Statistics, 2001
3. Hepatocellular carcinoma - Cause, treatment and metastasis
4. Experience of 1000 patients who underwent hepatectomy for small hepatocellular carcinoma
5. Progress in research of liver surgery in China
6. Clinical characteristics and outcome of a cohort of 101 patients with hepatocellular carcinoma
7. Hepatocellular carcinoma in central Sydney: A 10 year review of patients seen in a medical oncology department
8. Review of 336 patients with hepatocellular carcinoma at Songklanagarind Hospital
9. Serum vascular endothelial growth factor is a potential biomarker of metastatic recurrence after curative resection of hepatocellular carcinoma
10. Hepatocellular carcinoma
11. The National Cancer Data Base Report on treatment patterns for hepatocellular carcinomas: Improved survival of surgically resected patients, 1985-1996
12. Natural history of inoperable hepatocellular carcinoma estrogen receptors' status in the tumor is the strongest prognostic factor for survival
13. Morphology and other prognostic factors of hepatocellular carcinoma
14. The factors affecting the recurrent rate after radical resection of liver cancer
15. What patients can survive disease free after complete resection for hepatocellular carcinoma? A multivariate analysis
16. Hepatitis viral status in patients undergoing liver resection for hepatocellular carcinoma
17. Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus
18. Surgical results in patients with hepatitis B-related hepatocellular carcinoma and positive hepatitis B early antigen
19. Effect of viral status on recurrence after liver resection for patients with hepatitis B virus-related hepatocellular carcinoma
20. Correlation of clinicopathologic features of resected hepatocellular carcinoma with hepatitis C virus genotype
21. Surgical outcome in cirrhotic patients with hepatitis C-related hepatocellular carcinoma
22. Hepatic function immediately after hepatectomy as a significant risk factor for early recurrence in hepatocellular carcinoma
23. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma
24. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: Long-term results of treatment and prognostic factors
25. Long-term prognosis after resection of hepatocellular carcinoma associated with hepatitis B-related cirrhosis
26. Postoperative prediction of and strategy for metastatic recurrent hepatocellular carcinoma according to histologic activity of hepatitis
27. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: Results in a series of 100 Italian patients
28. Natural killer cell activity in patients with hepatocellular carcinoma: A new prognostic indicator after hepatectomy
29. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma
30. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire
31. Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels
32. Presence of alpha-fetoprotein mRNA in blood correlates with outcome in patients with hepatocellular carcinoma
33. Clinical significance of alpha-fetoprotein mRNA during perioperative period in HCC
34. Postoperative detection of alpha-fetoprotein mRNA in blood as a predictor for metastatic recurrence of hepatocellular carcinoma
35. Hematogenous dissemination of hepatocytes and tumor cells after surgical resection of hepatocellular carcinoma: A quantitative analysis
36. Circulating tumor cell mRNAs in peripheral blood from hepatocellular carcinoma patients under radiotherapy, surgical resection or chemotherapy: A quantitative evaluation
37. Recurrence or metastasis of HCC: Predictors, early detection and experimental antiangiogenic therapy
38. Prospective evaluation of circulating hepatocytes by alpha-fetoprotein mRNA in humans during liver surgery
39. Detection of isolated disseminated tumor cells in bone marrow and blood samples of patients with hepatocellular carcinoma
40. Relationship between expression of α-fetoprotein messenger RNA and some clinical parameters of human hepatocellular carcinoma
41. Usefulness of Lens culinaris agglutinin A-reactive fraction of alpha-fetoprotein (AFP-L3) as a marker of distant metastasis from hepatocellular carcinoma
42. Prognostic significance of anatomical resection and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma
43. How should patients with hepatocellular carcinoma be staged? Validation of a new prognostic system
44. A prognostic index of the survival of patients with unresectable hepatocellular carcinoma after transcatheter arterial chemoembolization
45. Risk factors, prevention, and management of postoperative recurrence after resection of hepatocellular carcinoma
46. Surgical results for hepatocellular carcinoma with macroscopic portal vein tumor thrombosis
47. Proposal of invasiveness score to predict recurrence and survival after curative hepatic resection for hepatocellular carcinoma
48. The influence of perioperative blood transfusion on intrahepatic recurrence after curative resection of hepatocellular carcinoma
49. Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma
50. Factors regulating tumor pressure in hepatocellular carcinoma and implications for tumor spread
51. Analysis of factors affecting outcome after hepatectomy of patients with liver cirrhosis and small hepatocellular carcinoma
52. Hepatocellular carcinoma in Central Europe: Prognostic features and survival
53. Prediction of recurrence and extratumor spread of hepatocellular carcinoma following resection
54. Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection
55. The clinical significance of lymph node metastases in patients undergoing surgery for hepatocellular carcinoma
56. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration
57. Evaluation of a simplified staging system for prognosis of hepatocellular carcinoma
58. Hepatocellular carcinoma: Current surgical management
59. Combination therapy with transcatheter arterial chemoembolization and percutaneous microwave coagulation therapy for hepatocellular carcinoma
60. Liver resection for cancer
61. Retrospective analysis of type of hepatic resection for hepatocellular carcinoma
62. Evaluation of major hepatic resection for small hepatocellular carcinoma
63. Hepatic resection for hepatocellular carcinoma
64. Efficacy of major hepatic resection for large hepatocellular carcinoma
65. Extent of hepatic resection as a prognostic factor for small, solitary hepatocellular carcinomas
66. Hepatectomy for hepatocellular carcinoma: The surgeon's role in long-term survival
67. Perioperative blood transfusion as a prognostic indicator in patients with hepatocellular carcinoma
68. Neoadjuvant and adjuvant therapy for operable hepatocellular carcinoma
69. Prognostic factors after hepatic resection for hepatocellular carcinoma associated with Child-Turcotte class B and C cirrhosis
70. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma
71. Effect of preoperative transcatheter arterial chemoembolization on tumor cell activity in hepatocellular carcinoma
72. Preoperative transcatheter arterial chemoembolization and prognosis of patients with hepatocellular carcinomas: Retrospective analysis of 120 cases
73. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: A clinicopathologic study
74. The effect of preoperative transcatheter hepatic arterial chemoembolization on disease-free survival after hepatectomy for hepatocellular carcinoma
75. Preoperative portal vein embolization improves prognosis after right hepatectomy for hepatocellular carcinoma in patients with impaired hepatic function
76. Preoperative main portal branch transection combined with liver locoregional transarterial neo and adjuvant immunochemotherapy for patients with hepatocellular carcinoma
77. Preoperative administration of 5-FU and interferon beta may prevent recurrence of hepatitis B and C virus
78. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial
79. Use of transcatheter arterial infusion of anticancer agents with lipiodol to prevent recurrence of hepatocellular carcinoma after hepatic resection
80. Adjuvant hepatic arterial infusion chemotherapy after radical hepatectomy for hepatocellular carcinoma - Results of long-term follow-up
81. Resection of hepatocellular carcinoma
82. Prophylactic chemolipiodolization for postoperative hepatoma patients
83. Prospective case-controlled trial of adjuvant chemotherapy after resection of hepatocellular carcinoma
84. Postoperative adjuvant chemotherapy after curative resection of hepatocellular carcinoma: A randomized controlled trial
85. Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: Metaanalysis of three randomized controlled trials
86. The value of postoperative hepatic regional chemotherapy in prevention of recurrence after radical resection of primary liver cancer
87. The studies on the recurrence and metastasis of hepatocellular carcinoma
88. Transcatheter arterial chemoembolization for postoperative residual tumor of hepatocellular carcinoma
89. Appraisal of postoperative transcatheter arterial chemoembolization (TACE) for prevention and treatment of hepatocellular carcinoma recurrence
90. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial
91. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: A pilot study
92. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer
93. Influence of previous interferon therapy on recurrence after resection of hepatitis c virus-related hepatocellular carcinoma
94. High-dose and long-term therapy with interferon-alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential
95. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial